

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

(I) RESIGNATION OF DIRECTORS, PRESIDENT AND FINANCIAL CONTROLLER, AND CHANGES IN MEMBERS OF BOARD COMMITTEES;
(II) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR, VICE CHAIRMAN AND SENIOR MANAGEMENT; AND
(III) CHANGE OF AUTHORIZED REPRESENTATIVE

I. RESIGNATION OF DIRECTORS, PRESIDENT AND FINANCIAL CONTROLLER, AND CHANGES IN MEMBERS OF BOARD COMMITTEES

The Board of Directors (the “**Board**”) of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, on 28 February 2026, it received written resignations from Mr. Xu Guoxiang (徐國祥先生) (“**Mr. Xu**”) and Mr. Tao Desheng (陶德勝先生) (“**Mr. Tao**”). Mr. Xu, having reached the retirement age, voluntarily resigned from the positions of Executive Director, Vice Chairman and Vice President of the Company, and will not hold any position in the Company, its subsidiaries, or associated companies after resignation. Mr. Tao, having reached the retirement age, voluntarily resigned from the positions of Non-executive Director, Vice Chairman, member of the Nomination Committee of the Board and member of the Strategy Committee of the Board, and will not hold any position in the Company, its subsidiaries, or associated companies after resignation. The resignations of Mr. Xu and Mr. Tao shall take effect from the date the resignations were delivered to the Board (i.e. 28 February 2026).

According to the requirements of the Terms of Reference of the Board Nomination Committee (《董事會提名委員會職權範圍》) and the Terms of Reference of the Board Strategy Committee (《董事會戰略委員會職權範圍》), the resignation of Mr. Tao will result in the number of members of the Board Nomination Committee and the Board Strategy Committee being less than three. The Company will, in accordance with the relevant provisions of the Company Law of the People's Republic of China (《中華人民共和國公司法》), the Articles of Association (《公司章程》) and relevant working rules of the Board committees, complete the election of directors and members of the Board committees as soon as possible in accordance with statutory procedures.

As at the date of this announcement, Mr. Xu holds 783,800 A shares of the Company, Mr. Tao holds 733,800 A shares of the Company, and Ms. Hou Xuemei, the spouse of Mr. Tao, holds 146,806 A shares of the Company. Mr. Xu and Mr. Tao have confirmed that there are no disagreements between them and the Board, and there are no other matters relating to their resignations that need to be brought to the attention of the shareholders of the Company.

During their tenure, Mr. Xu and Mr. Tao fulfilled their duties conscientiously and worked diligently, making significant contributions to the sustained healthy development of the Company. The Board expresses its sincere gratitude to Mr. Xu and Mr. Tao for their hard work during their tenure.

The Board of the Company announces that, on 28 February 2026, it received written resignations from Mr. Tang Yanggang (唐陽剛先生) (“**Mr. Tang**”) and Ms. Si Yanxia (司燕霞女士) (“**Ms. Si**”). Due to job adjustment, Mr. Tang voluntarily resigned from the position of President of the Company, and will continue to serve as Executive Director of the Company, and hold positions in the subsidiaries and associated companies of the Company after resignation. Ms. Si, having reached the retirement age, voluntarily resigned from the positions of Vice President and Financial Controller of the Company, as well as all positions she held in the Company and its subsidiaries. The resignations of Mr. Tang and Ms. Si shall take effect from the date the resignation letters were delivered to the Board (i.e. 28 February 2026).

As at the date of this announcement, Mr. Tang holds 344,963 A shares of the Company, and Ms. Si holds 434,423 A shares of the Company. Mr. Tang and Ms. Si have confirmed that there are no disagreements between them and the Board, and there are no other matters relating to their resignations that need to be brought to the attention of the shareholders of the Company.

During their tenure, Mr. Tang and Ms. Si fulfilled their duties conscientiously and worked diligently, making significant contributions to the sustained healthy development of the Company. The Board expresses its sincere gratitude to Mr. Tang and Ms. Si for their hard work during their tenure.

II. PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR, VICE CHAIRMAN AND SENIOR MANAGEMENT

The Board of the Company is pleased to announce that, upon review and approval by the Nomination Committee of the Board, the Board has resolved to nominate Mr. Liu Daping (劉大平先生) (“**Mr. Liu**”) as a candidate for Executive Director of the 11th Session of the Board of the Company. His term will commence from the date of approval at the shareholders' general meeting until the expiry of the term of the 11th Session of the Board of the Company. The appointment of Mr. Liu is subject to approval by the shareholders of the Company at the shareholders' meeting.

The Board of the Company further announces that, upon review and approval by the Nomination Committee of the Board, the Board has resolved to appoint Mr. Liu as the President of the Company, with effect from 28 February 2026, for a term expiring on the date of expiry of the 11th Session of the Board of the Company.

The biography of Mr. Liu is as follows:

Mr. Liu Daping, aged 38, currently serves as the Vice President of the Company. He graduated from China Pharmaceutical University (中國藥科大學) with a bachelor's degree in pharmaceutics. He currently serves as director and senior management in certain subsidiaries of the Group, including Livzon Pharmaceutical Research Institute of Livzon Group (麗珠集團麗珠醫藥研究所) and Livzon Pharmaceutical Factory of Livzon Group (麗珠集團麗珠製藥廠). From September 2010 to July 2019, he successively served as a technician, workshop director and production director of Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱製藥有限公司). From July 2019 to June 2021, he served as the Executive Deputy General Manager of Shenzhen TaiTai Pharmaceutical Co., Ltd. (深圳太太藥業有限公司) From July 2021 to January 2024, he served as the Deputy Director of the Production Management Center of Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司), overseeing Shenzhen TaiTai Pharmaceutical Co., Ltd. (serving as General Manager from October 2021 to January 2024) and Joincare Haibin Pharmaceutical Co., Ltd. (健康元海濱藥業有限公司). He has served as the Vice President of the Company since January 2024. As at the date of this announcement, Mr. Liu does not hold any shares of the Company.

Subject to the approval of his appointment by the shareholders' meeting, the Company will enter into a director service contract with Mr. Liu. As the Executive Director and concurrently the President of the Company, Mr. Liu will receive an annual director's fee of RMB 96,000 (pre-tax) during his term, and will be entitled to remuneration for his service as the President of the Company. The directors' fee and remuneration of Mr. Liu have been determined by the Board with reference to his duties and responsibilities in the Company, the Company's remuneration policy and the market salary range for the position.

Save as disclosed above, Mr. Liu confirmed: (i) he has not served as a director of any other listed companies in the past three years, nor does he hold any other major appointments or professional qualifications; (ii) he does not hold any other positions in the Company or any member companies of the Group; (iii) he has no relationship with any director, supervisor, senior management, major shareholder or controlling shareholder of the Company or any of its subsidiaries; and (iv) as at the date of this announcement, he does not have any interest in the shares of the Company as defined in Section XV of the Securities and Futures Ordinance.

The Board of the Company is pleased to announce that Mr. Tang Yanggang, an Executive Director of the Company, is appointed as the Vice Chairman of the 11th Session of the Board of the Company, officially taking office on 28 February 2026, with a term until the expiry of the term of the 11th Session of Board of the Company, and is eligible for re-election upon the expiry of the term.

The biography of Mr. Tang is as follows:

Mr. Tang Yanggang, aged 56, currently serves as an Executive Director, a member of the Remuneration and Assessment Committee, a member of the Strategy Committee and a member of the Environmental, Social and Governance Committee of the Company, and serves as a director in certain subsidiaries of the Group, including Zhuhai Livzon Reagents Co., Ltd. (珠海麗珠試劑股份有限公司) and Livzon Group Limin Pharmaceutical Factory (麗珠集團利民製藥廠). He graduated from Sichuan University (四川大學) in 1992 with a bachelor's degree in microbiology. He is a Senior Pharmaceutical Engineer. He joined Livzon Group Xinbeijiang Pharmaceutical Co., Ltd. (麗珠集團新北江製藥股份有限公司) (“**Xinbeijiang Pharma**”) in 2008, and successively served as the Technical Director, General Manager, Chairman and Party Secretary of Xinbeijiang Pharma. He has served as the Chairman of Xinbeijiang Pharma since July 2015. From July 2015 to October 2020, he served as the General Manager of the API Business Unit of the Company. He also serves as the Vice President of the China Association of Traditional Chinese Medicine (中國中藥協會), the Vice President of the Guangdong Pharmaceutical Association (廣東省藥學會), a member of the Zhuhai Municipal Committee of the CPPCC, and the Vice President of the Qingyuan Entrepreneurs Association (清遠企業家協會). He has served as a member of the Standing Committee of the Executive Committee of the Zhuhai Federation of Industry and Commerce (珠海市工商聯執行委員會) and an executive member of the Standing Council of the Zhuhai General Chamber of Commerce (珠海市總商會理事會) since March 2023. He served as the Executive Vice President of the Company from July to December 2018. He served as the President of the Company from December 2018 to February 2026. He has served as the Executive Director of the Company since February 2019.

Subject to the approval of his appointment by the Board of the Company, Mr. Tang will receive an annual directors' fee of RMB3 million (pre-tax) during his term. The director's fee of Mr. Tang has been determined by the Board with reference to his duties and responsibilities in the Company, the Company's remuneration policy and the market salary range for the position.

Save as disclosed above, Mr. Tang confirmed: (i) he has not served as a director of any other listed companies in the past three years, nor does he hold any other major appointments or professional qualifications; (ii) he does not hold any other positions in the Company or any member companies of the Group; (iii) he has no relationship with any director, supervisor, senior management, major shareholder or controlling shareholder of the Company or any of its subsidiaries; and (iv) as at the date of this announcement, he does not have any interest in the shares of the Company as defined in Section XV of the Securities and Futures Ordinance.

The Board of the Company is pleased to announce that Mr. Wang Sheng (王勝先生) (“**Mr. Wang**”) is appointed as the Financial Controller of the Company, with effect from 28 February 2026, for a term expiring on the date of expiry of the 11th Session of the Board of the Company.

The biography of Mr. Wang is as follows:

Mr. Wang Sheng, aged 44, currently serves as the Chief Financial Officer of the Company. He graduated from the Department of Thermal Science and Energy Engineering of the University of Science and Technology of China (中國科學技術大學) in July 2005 with a Bachelor of Engineering degree; he completed the Advanced Tax Director Training Class of Shanghai University of Finance and Economics (上海財經大學) in August 2013 and obtained the qualification of Senior Tax Planner. He joined Deloitte (德勤會計師事務所) in July 2005 and served as a Tax Manager and Consulting Consultant; he joined Takeda Pharmaceutical Group (武田制藥集團) in October 2012 and served as the Hong Kong Regional Financial Controller, Greater China and North Asia Tax Head, etc. He joined the Company in September 2025 and served as the Chief Financial Officer. Mr. Wang Sheng is a member of the Chartered Institute of Management Accountants, and holds professional qualifications such as Certified Practising Accountant (Australia), Chartered Global Management Accountant, and Certified Tax Agent (China).

As at the date of this announcement, Mr. Wang does not hold any shares of the Company.

The Board of the Company is pleased to announce that Mr. Chen Zhihua (陳志華先生) (“**Mr. Chen**”) is appointed as the Vice President of the Company, with effect from 28 February 2026, for a term expiring on the date of expiry of the 11th Session of the Board of the Company.

The biography of Mr. Chen is as follows:

Mr. Chen Zhihua, aged 45, currently serves as the Deputy General Manager of the Prescription Drug Business Unit and the General Manager of the Prescription Drug North Region of the Company. He graduated from Beijing Jiaotong University (北京交通大學) with a bachelor’s degree in business administration. From October 2005 to September 2019, he served as a sales representative and regional manager of Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司); from October 2019 to March 2021, he served as the sales director of the Northern Region at Chengdu Easton Biopharmaceuticals Co., Ltd. (成都苑東生物製藥股份有限公司); he joined the Company in March 2021 and served as the General Manager of Beijing Region of the Prescription Drug Business Unit; from January 2024 to March 2025, he served as the General Manager of the North China Region of the Prescription Drug Business Unit; he has served as the Assistant to the President since March 2025; and since April 2025, he has served as the Deputy General Manager of the Prescription Drug Business Unit and the General Manager of the Prescription Drug North Region of the Company.

As at the date of this announcement, Mr. Chen does not hold any shares of the Company.

III. CHANGE OF AUTHORIZED REPRESENTATIVE

The Board of the Company is pleased to announce that the authorized representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited* (香港聯合交易所有限公司) is changed from Mr. Tang to Mr. Liu, effective from the date on which Mr. Liu's appointment as an Executive Director is approved by the shareholders of the Company at the shareholders' meeting. With effect from the date of, the aforementioned arrangement, the authorized representatives of the Company shall be Mr. Liu Daping and Ms. Liu Ning (劉寧女士), the Company Secretary.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Liu Ning
Company Secretary

Zhuhai, China
1 March 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director of the Company is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

* *For identification purpose only*